The Road to Cures Series: CAR-T Therapy: What’s in the CARds? – Module 1 of 5

Program Overview

This activity provides an overview of CAR T-cell development, available CAR T-cell products for blood cancers, and important side effects of CAR T-cell therapy.

This activity will cover the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.

Credit Expired

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Upon completion of this activity, participants should be better able to:

Describe the current state of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies

Activity Faculty

Carl H. June, MD

Richard W. Vague Professor, Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Featured RMEI CE Activities – Earn CE Credit(s)

The Road to Cures Series: CAR-T Therapy: What’s in the CARds? – Module 1 of 5

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Carl H. June, MD

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe